Unknown

Dataset Information

0

Insights into pediatric rhabdomyosarcoma research: Challenges and goals.


ABSTRACT: Overall survival rates for pediatric patients with high-risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add biologically targeted agents to conventional cytotoxic drugs. One example of this type of combination is the addition of the WEE1 inhibitor AZD1775 to the conventional cytotoxic chemotherapeutics, vincristine and irinotecan.

SUBMITTER: Yohe ME 

PROVIDER: S-EPMC6707829 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Insights into pediatric rhabdomyosarcoma research: Challenges and goals.

Yohe Marielle E ME   Heske Christine M CM   Stewart Elizabeth E   Adamson Peter C PC   Ahmed Nabil N   Antonescu Cristina R CR   Chen Eleanor E   Collins Natalie N   Ehrlich Alan A   Galindo Rene L RL   Gryder Berkley E BE   Hahn Heidi H   Hammond Sharon S   Hatley Mark E ME   Hawkins Douglas S DS   Hayes Madeline N MN   Hayes-Jordan Andrea A   Helman Lee J LJ   Hettmer Simone S   Ignatius Myron S MS   Keller Charles C   Khan Javed J   Kirsch David G DG   Linardic Corinne M CM   Lupo Philip J PJ   Rota Rossella R   Shern Jack F JF   Shipley Janet J   Sindiri Sivasish S   Tapscott Stephen J SJ   Vakoc Christopher R CR   Wexler Leonard H LH   Langenau David M DM  

Pediatric blood & cancer 20190621 10


Overall survival rates for pediatric patients with high-risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add b  ...[more]

Similar Datasets

| S-EPMC5486973 | biostudies-literature
| S-EPMC6677781 | biostudies-literature
2004-03-13 | GSE967 | GEO
| S-EPMC7344174 | biostudies-literature
| S-EPMC3488193 | biostudies-literature
| S-EPMC5763363 | biostudies-other
| S-EPMC8573171 | biostudies-literature
| S-EPMC6001160 | biostudies-literature
| S-EPMC5135356 | biostudies-literature
| PRJNA238611 | ENA